Afimetoran

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Systemic Lupus ErythematosusDrug

134 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

1

Rituxan

Roche

Phase 3

92

Medrol

Pfizer

Phase 3

53

Rinvoq

AbbVie

Phase 3

34

Cytoxan

BBaxter Healthcare Corporation

Phase 3

125

Gazyva

Roche

Phase 3

26

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

37

Rapamune

PPrism Pharmaceuticals

Phase 3

18

Ianalumab

Novartis

Phase 3

39

Fludara

Sanofi

Phase 2

610

Glucocorticoid

AbbVie

Phase 3

1Show 44 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Drug1 trial

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

Recruiting·Bristol-Myers Squibb·Phase 1·NCT05866627·76 enrolled

Midazolam1 trial

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

Completed·Bristol-Myers Squibb·Phase 1·NCT05901714·65 enrolled

Systemic Lupus Erythematosus1 trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants With Active Systemic Lupus Erythematosus

Active, not recruiting·Bristol-Myers Squibb·Phase 2·NCT04895696·248 enrolled

Details

Drug Info

Related News